Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
US Department of Justice
AstraZeneca
Johnson and Johnson
Queensland Health
Dow
Medtronic
QuintilesIMS
McKesson
Fuji

Generated: February 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,895,612

« Back to Dashboard

Which drugs does patent 8,895,612 protect, and when does it expire?

Patent 8,895,612 protects INJECTAFER and is included in one NDA.

This patent has fifteen patent family members in fourteen countries.
Summary for Patent: 8,895,612
Title:Methods and compositions for administration of iron
Abstract: The present invention generally relates to treatment of iron-related conditions with iron carbohydrate complexes. One aspect of the invention is a method of treatment of iron-related conditions with a single unit dosage of at least about 0.6 grams of elemental iron via an iron carbohydrate complex. The method generally employs iron carbohydrate complexes with nearly neutral pH, physiological osmolarity, and stable and non-immunogenic carbohydrate components so as to rapidly administer high single unit doses of iron intravenously to patients in need thereof.
Inventor(s): Helenek; Mary Jane (Brookville, NY), Tokars; Marc L. (Douglassville, PA), Lawrence; Richard P. (Calverton, NY)
Assignee: Luitpold Pharmaceuticals, Inc. (Shirley, NY)
Application Number:14/100,717
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Drugs Protected by US Patent 8,895,612

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Luitpold Pharms Inc INJECTAFER ferric carboxymaltose INJECTABLE;INTRAVENOUS 203565-001 Jul 25, 2013 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y METHOD OF TREATMENT OF IRON-RELATED CONDITIONS WITH AT LEAST 0.6 GRAMS OF ELEMENTAL IRON VIA AN IRON CARBOHYDRATE COMPLEX, WITH A SUBSTANTIALLY NON-IMMUNOGENIC CARBOHYDRATE COMPONENT, IN ABOUT 15 MINUTES OR LESS. ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,895,612

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,754,702 Methods and compositions for administration of iron ➤ Try a Free Trial
8,431,549 Methods and compositions for administration of iron ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,895,612

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2007205167 ➤ Try a Free Trial
Canada 2635894 ➤ Try a Free Trial
Canada 2953964 ➤ Try a Free Trial
China 101365458 ➤ Try a Free Trial
Cyprus 1118780 ➤ Try a Free Trial
Denmark 1973549 ➤ Try a Free Trial
European Patent Office 1973549 ➤ Try a Free Trial
European Patent Office 2626074 ➤ Try a Free Trial
European Patent Office 3081219 ➤ Try a Free Trial
Spain 2602433 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Medtronic
Boehringer Ingelheim
Healthtrust
Accenture
Daiichi Sankyo
Baxter
AstraZeneca
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot